Efficas, Inc., a health science and technology development company, recently announced that it has secured $14.5 million in Series B financing bringing the total investment in the company since its founding in 2003 to $23 million.

LSP BioVentures Inc., Cambridge, Mass., is leading the Series B round. Unilever Technology Ventures joins LSP as a new investor. Returning Series A investors Burrill and Company, Great Spirit Ventures, JP Morgan Bay Area Equity Fund and Prolog Ventures also participated in the financing. Seven Hills Partners, San Francisco, acted as exclusive placement agent for Efficas.

"We are very pleased to have our Series B funding led by a firm of the stature of LSP," said Mark A. Braman, President and CEO of Efficas. "We consider LSP a valued partner who shares our belief in the growth prospects for Efficas and our portfolio of products. We are pleased that Unilever Technology Ventures and our returning investors also share this vision for our future."

Efficas’ first products, introduced earlier this year, include the Efficas™ Care line of medical foods that function as “leukotriene inhibitors” for the dietary management of allergic conditions such as asthma, eczema and allergies. The Series B round investment funds will be used for further development and commercialization of Efficas' pipeline of clinically proven bioactive compounds.

Jorg Riesmeier, PhD, General Partner of LSP BioVentures Inc. and new Board member of Efficas said, “With health and wellness as an investment focus area for LSP BioVentures, we believe strongly in the area of medical foods. Efficas has a leading competitive position in this space due to the science that underpins the products and the commercialization expertise of the management team. This combination is unique and will ensure the future success of the company.”